Highlights for the Quarter
• Optiscan revealed InForm™, its next generation microscopic medical imaging device specifically designed for pathology workflows.
• Optiscan received $1.775m R&D tax refund, $1.0m more than in previous years, due to the successful Advance and Overseas Finding application.
• A comprehensive review of operations, sales and marketing functions, and clinical and regulatory strategy occurred, which resulted in some significant outcomes:
➢ New key executive appointments were made, including the appointment of a Chief Financial Officer, Chief Commercial Officer and Director of Clinical & Regulatory Affairs, to implement the Company’s transformation plan that is strategically focussed on clinical, regulatory and commercial outcomes;
➢ A reorganisation of R&D, manufacturing and product assembly facilities to increase efficiency and meet demand for investigational devices and planned future growth.
Optiscan’s Chief Executive Officer and Managing Director, Dr. Camile Farah, commented:
“Our achievements over the March 2025 quarter have further demonstrated Optiscan’s ability to deliver on its strategic goals, which include an ongoing expansion of its product portfolio. The reveal of our InForm™ device, a realisation of the hard work put in by our R&D team, represents a watershed moment in the Company’s product development strategy. The device significantly advances the evolution of digital pathology, and has the ability to massively improve the entire pathology workflow from bedside to laboratory and beyond from multiple perspectives - speed, accuracy and the flexibility of testing, analysis and diagnosis included.
“As Optiscan has continued to evolve and grow, we thought the time was right to undertake a comprehensive review of our operations to maximise the outputs from this growth process. The key outcomes from this review were a number of new executive appointments that better position the Company to meet its clinical, regulatory and commercial goals, all while delivering an ongoing expansion of the Company’s product portfolio. I am pleased to say that the new Sales & Marketing team coming out of this review process has hit the ground running, and is now more actively pursuing global development and sales opportunities for Optiscan’s suite of Medtech offerings. Looking to the future, I’m excited by what’s ahead as we move into the next stage of our transformation journey.”
To read the full report, please click here
About us:
About Optiscan Imaging
Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.
Using a revolutionary "tissue contact" method, Optiscan’s patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.
The global addressable market for Optiscan’s medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.
To learn more about Optiscan, visit www.optiscan.com
Contact details:
Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
+61 3 9538 3333
[email protected]
Media & Investor Enquiries
The Capital Network
Julia Maguire
+61 2 7257 7338
[email protected]
